Summary & Overview
CPT 81538: Lung Cancer Prognostic Proteomic Serum Assay
CPT code 81538 covers a lab-developed prognostic assay for lung cancer that uses mass spectrometry to quantify eight serum proteins (including amyloid A) and applies a predictive algorithm to report likelihood of overall survival as good versus poor. This code matters nationally because prognostic molecular tests can influence clinical decision pathways, inform patient counseling, and factor into coverage and payment policy debates for precision oncology diagnostics.
Key payers examined in this context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical and laboratory workflow for the assay, typical sites of service, and payer relevance. The publication summarizes national benchmark considerations for coverage and coding recognition, highlights clinical context for lung cancer prognostication, and outlines areas where policy updates or clarifications may affect utilization and reimbursement decisions.
The analysis provides practical reference material for revenue cycle, laboratory operations, and oncology program leaders seeking concise information about coding, service definition, and payer landscape for this prognostic proteomic assay. Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Billing Code Overview
CPT code 81538 describes a laboratory-based prognostic test for patients with lung cancer. The service includes technical laboratory processing of a serum specimen using mass spectrometry to measure a panel of eight proteins (including amyloid A) and the application of a predictive algorithm that classifies overall survival likelihood as good versus poor.
Service Type: Clinical laboratory — molecular/proteomic prognostic test
Typical Site of Service: Clinical laboratory or reference laboratory; specimens collected in outpatient clinics, hospital outpatient departments, or other ambulatory settings and sent to a diagnostic lab for analysis
Clinical & Coding Specifications
Clinical Context
A 64-year-old patient with a history of non–small cell lung cancer (NSCLC) presents during oncology follow-up to assist prognostic assessment after systemic therapy. The oncologist orders a serum-based proteomic prognostic test processed with mass spectrometry that measures eight proteins, including serum amyloid A, and runs a predictive algorithm to classify overall survival likelihood as "good" versus "poor." A phlebotomy draw is performed in the outpatient oncology clinic or a reference laboratory collection center. The blood specimen is shipped to a central laboratory with mass spectrometry capability. In the lab, a trained clinical laboratory scientist performs the technical steps: sample preparation, protein quantitation by mass spectrometry, quality control, and runs the algorithm that integrates the protein panel (and any allowable clinical data elements) to generate a prognostic report. The final report is routed to the ordering oncologist and uploaded to the electronic medical record to support care planning and patient counseling on prognosis and treatment strategy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When billing only the professional interpretation component if applicable for the laboratory-developed test when provider performs interpretation distinct from the technical lab service |